Literature DB >> 12803200

Update: severe acute respiratory syndrome--United States, June 4, 2003.

.   

Abstract

CDC continues to work with state and local health departments, the World Health Organization (WHO), and other partners to investigate cases of severe acute respiratory syndrome (SARS). This report updates SARS cases reported worldwide and in the United States and summarizes changes in CDC's recommendations for travel to Singapore and Hong Kong and the resulting modification to the interim U.S. case definition for SARS.

Entities:  

Mesh：

Year:  2003        PMID： 12803200

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN： 0149-2195            Impact factor:   17.586


  5 in total

Review 1.  [Severe acute respiratory syndrome epidemics: the end or a hiatus of the epidemic?].

Authors:  Angela Domínguez; Francesc Gudiol; Tomás Pumarola; Lluís Salleras
Journal:  Med Clin (Barc)       Date:  2003-09-20       Impact factor: 1.725

2.  Using an integrated infection control strategy during outbreak control to minimize nosocomial infection of severe acute respiratory syndrome among healthcare workers.

Authors:  M-Y Yen; Y E Lin; I-J Su; F-Y Huang; F-Y Huang; M-S Ho; S-C Chang; K-H Tan; K-T Chen; H Chang; Y-C Liu; C-H Loh; L-S Wang; C-H Lee
Journal:  J Hosp Infect       Date:  2005-09-08       Impact factor: 3.926

Review 3.  Blood safety and the choice of anti-hemophilic factor concentrate.

Authors:  Leonard A Valentino; Veeral M Oza
Journal:  Pediatr Blood Cancer       Date:  2006-09       Impact factor: 3.167

4.  Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach.

Authors:  Abida Batool; Nousheen Bibi; Farhat Amin; Mohammad Amjad Kamal
Journal:  Eur J Pharmacol       Date:  2020-12-01       Impact factor: 4.432

5.  America's emergency care system and severe acute respiratory syndrome: are we ready?

Authors:  James J Augustine; Arthur L Kellermann; Jeffrey P Koplan
Journal:  Ann Emerg Med       Date:  2004-01       Impact factor: 5.721
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.